Stock ASND ASCENDIS PHARMA A/S
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Ascendis Pharma A/S

Equities

ASND

US04351P1012

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-22 pm EDT 		5-day change 1st Jan Change
131.1 USD +6.75% Intraday chart for Ascendis Pharma A/S +5.72% +4.12%
May. 22 European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading MT
May. 16 Morgan Stanley Adjusts Ascendis Pharma Price Target to $140 From $116, Maintains Equal Weight Rating MT

Evolution of the average Target Price on Ascendis Pharma A/S

Price target over the last 5 years

History of analyst recommendation changes

8ac887faa1d09a.rcQMBPdU_PXI2crZLEyoxUnd7XmSXbcMuvttCWBlsXI.6bZHM6Y8z6-kqvusQHndshHlgTzzOedpjJwGbFdQgiCblXYwuB-ooLGUoQ~616059d0645af181e1b6738030ee56d9

Analyst Recommendations on Ascendis Pharma A/S

Morgan Stanley Adjusts Ascendis Pharma Price Target to $140 From $116, Maintains Equal Weight Rating MT
Paycom Software Insider Sold Shares Worth $503,551, According to a Recent SEC Filing MT
JPMorgan Adjusts Ascendis Pharma A/S Price Target to $167 From $165, Maintains Overweight Rating MT
Wells Fargo Raises Ascendis Pharma Price Target to $260 From $196, Maintains Overweight Rating MT
Citigroup Raises Price Target on Ascendis Pharma to $182 From $146, Maintains Buy Rating MT
Wedbush Raises Ascendis Pharma's Pt to $225 From $207, Notes Multiple Catalysts Across Pipeline in Q4 2024; Keeps Outperform Rating MT
Cantor Fitzgerald Adjusts Price Target on Ascendis Pharma to $173 From $152, Keeps Overweight Rating MT
Wedbush Raises Price Target on Ascendis Pharma to $207 From $202, Maintains Outperform Rating MT
Wedbush Raises Ascendis Pharma's PT to $202 From $200, Keeps Outperform Rating; Says Among Top Picks for 2024 MT
Jefferies Starts Ascendis Pharma With Buy Rating, $150 Price Target MT
Wells Fargo Adjusts Ascendis Pharma Price Target to $149 From $137, Maintains Overweight Rating MT
Wedbush Adjusts Ascendis Pharma A/S Price Target to $200 From $192, Maintains Outperform Rating MT
Morgan Stanley Adjusts Price Target on Ascendis Pharma to $116 From $113, Maintains Equalweight Rating MT
Morgan Stanley Adjusts Price Target on Ascendis Pharma to $113 From $109, Maintains Equalweight Rating MT
Wedbush Raises Ascendis Pharma's Price Target to $192 From $187 After Model Adjustments, Keeps Outperform Rating MT
Wedbush Lifts Ascendis Pharma's Price Target to $187 From $186, Keeps Outperform Rating MT
Wedbush Lowers Ascendis Pharma's Price Target to $186 From $195 After Model Adjustments, Keeps Outperform Rating MT
Morgan Stanley Adjusts Ascendis Pharma's Price Target to $109 From $107, Keeps Equalweight Rating MT
Credit Suisse Raises Ascendis Pharma's Price Target to $89 From $82 After Q1 Skytrofa Revenue Beat Consensus, Keeps Neutral Rating MT
Oppenheimer Downgrades Ascendis Pharma to Perform From Outperform, Removes $148 Price Target MT
Citigroup Adjusts Ascendis Pharma Price Target to $146 From $163, Maintains Buy Rating MT
Morgan Stanley Downgrades Ascendis Pharma to Equalweight From Overweight, Adjusts Price Target to $108 From $151 MT
BofA Securities Adjusts Price Target on Ascendis Pharma to $92 From $132, Keeps Buy Rating MT
Wells Fargo Cuts Ascendis Pharma's Price Target to $139 From $177, Maintains Overweight Rating MT
Evercore ISI Lowers Ascendis Pharma's Price Target to $140 From $160, Maintains Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
121 EUR
Average target price
168.3 EUR
Spread / Average Target
+39.04%
High Price Target
244.9 EUR
Spread / Highest target
+102.34%
Low Price Target
128.8 EUR
Spread / Lowest Target
+6.43%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Ascendis Pharma A/S

Morgan Stanley
JPMorgan Chase
Wells Fargo Securities
Citigroup
Wedbush
Cantor Fitzgerald
Jefferies & Co.
Credit Suisse
Oppenheimer
BofA Securities
Evercore ISI
Goldman Sachs
SVB Securities LLC
Berenberg Bank
SVB Financial
SVB Leerink
Cowen
Canaccord Genuity
Stifel Nicolaus

Ratings for Ascendis Pharma A/S

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ASND Stock
  4. Consensus Ascendis Pharma A/S